ACA vs FLY

The company exhibits a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm safety from distress. Despite strong recent earnings growth (YoY EPS +71.4%, Earnings Growth YoY +335.3%) and solid revenue momentum (24.60% YoY), elevated valuation metrics (P/E 38.61 vs. sector avg 55.59) and bearish insider activity weigh on near-term outlook. The stock trades significantly above the Graham Number of $59.01, suggesting overvaluation for defensive investors, though growth investors may justify the premium. Analysts maintain a strong_buy consensus, but insider selling and modest dividend strength temper enthusiasm.

The company exhibits critical financial instability, evidenced by a Piotroski F-Score of 1/9, indicating severe weakness in fundamental health. While revenue growth is explosive at 538.40% YoY, this is offset by a catastrophic profit margin of -208.92% and an unsustainable Price/Sales ratio of 37.59. Despite strong short-term liquidity (Current Ratio 4.51), the massive earnings misses and lack of a path to profitability suggest the current valuation is driven by speculation rather than fundamentals.